Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Four-peptide repair stack · GHK-Cu / BPC-157 / TB-500 / KPV
A four-peptide repair stack — GHK-Cu, BPC-157, TB-500 and KPV — in one fill. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
Four peptides in one fill, picked because they touch tissue repair at four separate points. GHK-Cu carries copper and moves matrix genes. BPC-157, the gastric pentadecapeptide, works angiogenesis and the nitric-oxide axis. TB-500, a thymosin β4 fragment, sequesters actin and drives migration. KPV, the tail end of α-MSH, brings the anti-inflammatory signal.
Four mechanisms, four lineages, one vial. The reason to co-formulate rather than run four parallel preparations is to read whether those distinct effects show up together in the same tissue model — matrix, vascular, cytoskeletal, and immune, side by side.
Everything published sits at the single-peptide level: GHK-Cu on matrix genes and wound models, BPC-157 across tendon and gut repair, thymosin β4 / TB-500 on migration and closure, KPV on PepT1 uptake and colitis. The combination itself is the open part — whether matrix, vascular, cytoskeletal, and immune effects layer in a shared tissue-response model is the question the blend exists to put on the bench.
Read the four references and you get four distinct literatures. GHK-Cu: copper transport and the skin-regeneration gene programs Pickart mapped. BPC-157: angiogenesis and tendon/gut repair. TB-500: actin sequestration and wound closure. KPV: PepT1 uptake and a brake on colonic inflammation. KLOW is the point where those four records sit in a single tube.
The stack does not add a new mechanism — it tests an interaction. Put together, does the matrix, vascular, cytoskeletal, and immune work read additively in one model, or does the combination behave unlike the sum of four separate runs? That question is the reason to co-formulate.
No shared origin holds these four together — they were assembled, not discovered as a group. Pickart pulled GHK from human plasma in the 1970s and later connected the copper complex to skin-regeneration genes. BPC-157 emerged from gastric-juice screening; TB-500 from thymosin β4 cytoskeletal research; KPV from the hunt for the active piece of α-MSH.
Bringing them into one preparation is a deliberate convenience: a single controlled experiment that carries all four mechanistic stories at once, instead of four experiments run apart.
Pickart, L. et al. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration.
PubMedSikiric, P. et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(5):313–327.
PubMedGoldstein, A.L. et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 12(1):37–51.
PubMedChang, C.H. et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) 110(3):774–780.
PubMedChang, C.H. et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 19(11):19066–19077.
PubMedDalmasso, G. et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 134(1):166–178.
PubMedKolovrat, M. et al. (2020). Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World J Hepatol 12(5):184–206.
PubMedIndependent testing lot by lot: identity, purity, net content. The certificate arrives by email with your order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
